In a larger study including 225 PCa patients with biochemical recurrence, detection rates were 90.0% in patients with PSA ≥ 2 ng/mL and 54.0% in patients with PSA < 2 ng/mL, leading to treatment management in 74.0% of the patients 76. Here, KLK3 is linked to posterior cortical atrophy.